KPV
An anti-inflammatory tripeptide with real mechanism interest and the thinnest human evidence on the site.
Evidence tier: C (thinnest) (preclinical anti-inflammatory data; essentially no human trials) · Regulatory status in Canada: not approved; grey-market · Community risk profile: high — least-characterized of the common blend components, self-injected on the strength of mechanism alone.
C
What it is
KPV is a short tripeptide (lysine-proline-valine), a fragment of the hormone alpha-MSH, studied preclinically for anti-inflammatory effects. Online it's promoted for gut inflammation, skin conditions (rosacea, acne), and general inflammation, and it's the "anti-inflammatory" ingredient added to GLOW to make KLOW.
What People Use it For
Community: inflammatory bowel symptoms, rosacea/acne and other skin inflammation, general "calming inflammation." Taken orally, topically, or injected.
In blends: the K in KLOW (KPV + GHK-Cu + BPC-157 + TB-500).
What The Evidence Shows
Plausible mechanism, preclinical only. KPV has anti-inflammatory activity in cell and animal models — a real, interesting signal that explains the interest.
Human trials are essentially absent. There is no robust human efficacy or safety evidence for KPV as used in the community. Of the common blend components, it is the least characterized in humans.
Tier C, thinnest end: mechanism and preclinical data, not human evidence. Using it is acting on a hypothesis, not a demonstrated therapy.
Framing: the preclinical anti-inflammatory work is genuinely promising as science. That is not the same as knowing it works, at what dose, or safely, when self-administered by a person.
Regulatory Status - Canada
Not approved by Health Canada for any use. Sold as a "research chemical / not for human use" — legal shield, not a safety statement.
Risks & Red Flags
Human safety essentially uncharacterized — no completed human trials means no real adverse-event dataset. Absence of reported harm is not evidence of safety.
Route-specific risks: injected/DIY use adds sterility and unknown-dose risk; the compound's real behavior in humans at community doses is simply not established.
Opportunity cost is acute here: using KPV for gut or skin inflammation instead of getting the underlying condition diagnosed can waste the window when a treatable cause (e.g. IBD, a dermatologic condition) is best addressed (see delayed-care page).
Sourcing red flags
Unapproved, unverified product; identity/purity/dose unconfirmed.
"99% purity" ≠ potency or identity (see glossary).
In KLOW, KPV is one of four undisclosed doses in a single vial — you cannot confirm or attribute it (see KLOW page).
The Honest Bottom Line
KPV is the thinnest evidence page on Substrate, and that's the point of including it. The preclinical anti-inflammatory mechanism is genuinely interesting — it's a fragment of α-MSH with plausible gut and skin anti-inflammatory activity in lab models — but there is essentially no human trial evidence for the injected or oral product people are buying.
It shows up in gut-health and skin stacks (and in the GLOW/KLOW blends) on the strength of that mechanism story alone. Tier C means exactly this: a reasonable hypothesis, sold as if it were a proven treatment, with no human data and full gray-market sourcing risk. Interesting is not the same as demonstrated.
How To Lower Your Risk
Know you're acting on mechanism, not evidence — KPV is the clearest "promising in a dish, unproven in a person" case among the common compounds.
Inflammation deserves a diagnosis, not just a peptide: persistent gut or skin inflammation can have a treatable medical cause worth identifying (see clinician and delayed-care pages).
Single compound over the KLOW blend if using at all; sterile technique; third-party testing minimum.
Talk to a clinician — especially for GI symptoms, which can signal conditions that need real management.
Sources
Preclinical literature: anti-inflammatory activity for KPV (alpha-MSH fragment) in cell/animal models.
Human trials: none identified with posted efficacy/safety results for community uses.
Evidence characterization for this project. KPV sits at the thinnest end of Tier C — mechanism without human evidence — and the page is written to make that explicit rather than imply more.
Substrate is an independent educational harm-reduction resource. It is not medical, legal, or regulatory advice, and it is not a substitute for a licensed clinician. Compounds discussed are largely unapproved in Canada; nothing here endorses their use. Confirm anything health-related with a qualified professional. Built by a medical-sciences student — not a seller and not a clinic.